Quick answer: how Ozempic and Wegovy differ
- Same active ingredient: semaglutide (a GLP‑1 receptor agonist)
- Different primary indication:
- Ozempic: type 2 diabetes, with cardiovascular risk reduction benefits in eligible patients
- Wegovy: chronic weight management in adults (and in some jurisdictions adolescents) who meet criteria
- Different dose targets:
- Ozempic: typically titrated from 0.25 mg to 0.5 mg and 1.0 mg weekly (some markets have higher strengths; check your script)
- Wegovy: titrated from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg weekly (maintenance)
- Access and funding in Australia:
- Ozempic: may be PBS‑subsidised for eligible type 2 diabetes indications
- Wegovy: generally private purchase (not PBS); availability can vary by pharmacy
How they are the same
Both brands deliver semaglutide once weekly. Semaglutide is a GLP‑1 receptor agonist that helps lower blood glucose, reduce appetite and slow gastric emptying. Because the active medicine is identical, the core safety profile and many day‑to‑day experiences overlap.
- Weekly injection with a multi‑dose pen
- Gradual dose titration to improve tolerability
- Similar common side effects: nausea, vomiting, diarrhoea or constipation, abdominal discomfort, decreased appetite
- Serious risks are rare but can include pancreatitis and gallbladder disease—seek urgent care if severe abdominal pain occurs
Learn more about semaglutide itself: What Is Semaglutide?, Semaglutide Dosage Guide, Semaglutide Side Effects, Results Timeline.
Key differences: indication, dose and goals
Intended use
- Ozempic: on‑label for adults with type 2 diabetes. Any weight loss use is off‑label and should be discussed with your prescriber.
- Wegovy: on‑label for chronic weight management alongside diet and physical activity in eligible people meeting BMI or risk‑factor criteria.
Dose ceilings and expected outcomes
- Ozempic commonly maintains at 1.0 mg weekly (check your prescription; some strengths vary by market). Weight loss at these doses can occur but is typically less than with the higher Wegovy maintenance dose.
- Wegovy titrates to 2.4 mg weekly maintenance, the dose used in large weight‑management trials.
Access and PBS status in Australia
- Ozempic: may be PBS‑subsidised for eligible type 2 diabetes. See: Ozempic Australia Guide, Ozempic Cost, Ozempic Prescription.
- Wegovy: generally private payer, not PBS‑subsidised. See: Wegovy Australia Guide, Wegovy Cost, Wegovy Prescription.
Dosing and titration schedules
Both products increase slowly to reduce stomach‑related side effects. Always follow your own prescription.
- Ozempic (typical pattern): 0.25 mg weekly for 4 weeks → 0.5 mg weekly for 4 weeks → consider 1.0 mg weekly ongoing if prescribed.
- Wegovy: 0.25 mg weekly (4 weeks) → 0.5 mg (4 weeks) → 1.0 mg (4 weeks) → 1.7 mg (4 weeks) → 2.4 mg weekly maintenance if tolerated.
If side effects persist, clinicians may extend a step or pause dose increases. Switching between brands should be supervised so the weekly dose and timing are aligned.
Related reading: Semaglutide Dosage, Ozempic Side Effects, Wegovy Side Effects.
Cost, supply and how access works in Australia
- Prescription only: both require a script from an authorised prescriber.
- PBS:
- Ozempic: PBS‑eligible for type 2 diabetes criteria; not PBS for weight loss.
- Wegovy: generally not PBS; private pricing varies by pharmacy and strength.
- Supply: availability can vary by location and time; pharmacies may prioritise diabetes indications during shortages.
Deep dives: Semaglutide Prescription Australia, Semaglutide Cost Australia, Is Semaglutide Legal in Australia?.
Which should you ask your doctor about?
- You primarily need blood glucose control for type 2 diabetes → discuss Ozempic.
- Your main goal is medically supervised weight management and you meet criteria → discuss Wegovy.
- You’re weighing alternatives (dual‑agonist or oral options) → compare:
- Mounjaro vs Ozempic (tirzepatide vs semaglutide)
- Mounjaro vs Wegovy
- Rybelsus vs Ozempic (oral vs injectable)
- Wegovy vs Saxenda (weekly vs daily)
- Semaglutide vs Tirzepatide
Safety notes and who should not use semaglutide
Do not use semaglutide if you have a personal or family history of medullary thyroid carcinoma or MEN2, or if you are pregnant. Discuss your medical history, other medicines, and risks such as pancreatitis, gallbladder disease, severe gastrointestinal disease, and diabetic retinopathy with your clinician.
This page is general information only and not medical advice. Decisions should be made with a qualified health professional who can assess your situation.
Frequently asked questions
Is Ozempic the same as Wegovy?
They contain the same medicine (semaglutide) but are approved for different primary uses and reach different maintenance doses.
Which leads to more weight loss?
Wegovy is designed for chronic weight management and titrates to 2.4 mg weekly, the dose used in weight‑management trials. Ozempic dosing for diabetes is typically lower.
Can I get either on the PBS?
Ozempic may be PBS‑subsidised for eligible type 2 diabetes. Wegovy is generally not PBS‑subsidised and is usually paid privately.
Do side effects differ?
Side effects are similar because the active ingredient is the same. Tolerability often improves with slower titration and meal adjustments. Seek medical care for severe symptoms.
Get help choosing between Ozempic and Wegovy
Share a few details and a clinician‑supported team can point you toward the most relevant pages, eligibility criteria and next steps.
Prefer to browse? Start with these hubs: Weight Loss Injections Australia, GLP‑1 Australia Guide.
Final takeaway
Ozempic and Wegovy contain the same medicine but are built for different outcomes. Ozempic targets blood glucose control in type 2 diabetes; Wegovy targets chronic weight management and uses a higher maintenance dose.
Clarify your primary goal, eligibility and funding path with a clinician. If weight is your main focus, Wegovy is the on‑label semaglutide brand to discuss. If diabetes is the priority, Ozempic is the usual first conversation.